price
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Stock ticker
- PODD
- Company
- Insulet Corp.
- Industry
- Healthcare
- Category
- US
- Stock split / reverse split
- --
- Launch date
- May 15, 2007
- Listed exchange
- NASDAQ
Financials
Summary: PODD reported Revenue of 801.70M (+23.51%), beating expectations; EPS of 1.66 (+41.88%), beating expectations.
PODD conversion tables
 |  |
|---|---|
| 0.5 PODD | 65.82 USD |
| 1 PODD | 131.64 USD |
| 5 PODD | 658.2 USD |
| 10 PODD | 1,316.4 USD |
| |
|---|---|
| 0.5 USD | 0.0037982 PODD |
| 1 USD | 0.0075965 PODD |
| 5 USD | 0.037982 PODD |
| 10 USD | 0.075965 PODD |
More to explore
FAQ
PODD is trading at $131.64, -0.04% over the last 24 hours. Track live moves on the price chart at the top of this page.
The PODD stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. PODD is currently trading at $131.64, -0.04% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on PODD price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. PODD's P/E ratio is currently 24.61 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from PODD; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against PODD's historical range and other companies in the Healthcare sector.
Insulet Corp.'s market cap is currently 9.12B USD. Market cap is calculated as stock price × total shares outstanding.
Disclaimer
The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.
OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.